Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels

Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels

US Patent 8455469 · Granted Jun 4, 2013

Estimated economic value: $15,945,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals2017
N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals2017
Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharma2015
Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharma2013
Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors2013
Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use2013
6-substituted isoquinolines and isoquinolinones2013
Heteroarylacrylamides and their use as pharmaceuticals2012
Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine deriv2012
Improving vascular function with an inactivating mutant of a TRPC channel protei2012
Heteroaryl-substituted carboxamides and their use as pharmaceuticals2012
Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmace2011